Nicholas Company’s GSK GSK Stock Holding History

Nicholas Company’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-85,665	Closed	-$3.67M	–	219
2024 Q1	$3.67M	Sell	85,665 -75,775	-47%	-$3.12M	0.06%	205
2023 Q4	$5.98M	Sell	161,440 -42,215	-21%	-$1.52M	0.11%	180
2023 Q3	$7.38M	Sell	203,655 -855	-0.4%	-$30.3K	0.15%	136
2023 Q2	$7.29M	Buy	204,510 +18,150	+10%	+$651K	0.14%	150
2023 Q1	$6.63M	Buy	186,360 +10,135	+6%	+$355K	0.13%	166
2022 Q4	$6.19M	Buy	176,225 +60,355	+52%	+$2.01M	0.13%	163
2022 Q3	$3.41M	Buy	+115,870	New	+$4.39M	0.08%	207

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Nicholas Company's GSK Position: Q2 2024 in Review

Nicholas Company sold out of GSK (GSK) in Q2 2024, closing a stake of 85,665 shares — an estimated $3.67M sold.

Nicholas Company first reported a position in GSK in Q3 2022 and held it in 7 quarters. The position peaked at $7.38M in Q3 2023. 884 funds tracked by Wall St. Rank hold GSK as of Q2 2024.

Nicholas Company reported no remaining GSK position as of Q2 2024 after selling out during the quarter.
Nicholas Company sold 85,665 GSK shares in Q2 2024, an estimated $3.67M.
Nicholas Company first reported a position in GSK in Q3 2022 and held it in 7 quarters.
Nicholas Company's GSK position peaked at $7.38M in Q3 2023.
884 funds tracked by Wall St. Rank held GSK as of Q2 2024.

Based on Nicholas Company's 13F filing for Q2 2024, filed 24 Jul 2024.